Frova (Frovatriptan Succinate) Drug Information: Overdosage and Contraindications

Pill Identifier Search

May 27, 2012

Frova

Tension Headache »

Introduction

Tension headaches are the most common type of headaches among adults. They are commonly referred to as stress headaches.

A tension headache may appear periodically ("episodic," less than 15 days per month) or daily ("chronic," more than 15 days per month). An episodic tension headache may be described as a mild to moderate constant band-like pain, tightness, or pressure around the forehead or back of the head and neck.

These headaches may last from 30 minutes to several days. Episodic tension headaches usually begin gradually, and often occur in the middle of the day.

The "severity" of a tension headache increases significantly with its frequency. Chronic tension headaches come and go over a prolonged period of time. The pain is usually throbbing and affects the front, top, or sides of the head. Although the pain may vary in intensity throughout the day, the pain is almost always present. Chronic tension headaches do not affec...

Read the Tension Headache article »

« Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
Next »

Frova User Reviews >>

Frova

View the Headaches and Migraines Slideshow Pictures

A Visual Guide to Migraine Headaches Slideshow Pictures

Headache and Migraine Triggers Slideshow Pictures

Take the Migraines Quiz

font size

OVERDOSE

There is no direct experience of any patient taking an overdose of FROVA. The maximum single dose of frovatriptan given to male and female patients with migraine was 40 mg (16 times the clinical dose) and the maximum single dose given to healthy male subjects was 100 mg (40 times the clinical dose) without significant adverse events.

As with other 5-HT₁ receptor agonists, there is no specific antidote for frovatriptan. The elimination half-life of frovatriptan is 26 hours, therefore if overdose occurs, the patient should be monitored closely for at least 48 hours and be given any necessary symptomatic treatment.

The effects of hemo- or peritoneal dialysis on blood concentrations of frovatriptan are unknown.

CONTRAINDICATIONS

FROVA should not be given to patients with ischemic heart disease (e.g. angina pectoris, history of myocardial infarction, or documented silent ischemia), or to patients who have symptoms or findings consistent with ischemic heart disease, coronary artery vasospasm, including Prinzmetal's variant angina or other significant underlying cardiovascular disease (see WARNINGS).

FROVA should not be given to patients with cerebrovascular syndromes including (but not limited to) strokes of any type as well as transient ischemic attacks.

FROVA should not be given to patients with peripheral vascular disease including (but is not limited to) ischemic bowel disease (see WARNINGS)

FROVA should not be given to patients with uncontrolled hypertension (see WARNINGS). FROVA should not be administered to patients with hemiplegic or basilar migraine.

FROVA should not be used within 24 hours of treatment with another 5-HT₁ agonist, an ergotamine containing or ergot-type medication such as dihydroergotamine (DHE) or methysergide.

FROVA is contraindicated in patients who are hypersensitive to frovatriptan or any of the inactive ingredients in the tablets.

Last reviewed on RxList: 4/17/2012
This monograph has been modified to include the generic and brand name in many instances.